Tải xuống
Tóm tắt
Objective: Vinorelbine monotherapy has been shown to be effective in recurrent or metastatic nonsmall cell lung cancer. This study aimed at evaluating the treatment results of vinorelbine monotherapy in
lung cancer patients relapsed after curative treatment.
Patients and methods: Descriptive study of 56 non-small cell lung cancer patients who were treated
with vinorelbine monotherapy relapsed after curative treatment at National Cancer Hospital between June
2018 and August 2020.
Results: The mean age was 56.9 years old. Ratio male:female = 3.3:1. The percentage of
adenocarcinoma and squamous cell carcinoma was 67.9% and 26.8%, respectively. Most patients (76.8%)
relapsed within one year after curative treatment. The most common relapse sites were lung, bone, and
pleura (85.7%, 33.9%, 30.4% respectively).The total number of treatment cycles was 428 with the average
number of cycles was 6.1 ± 3.2, ranging from 2 to 21 cycles. Treatment response: no patient achieved
complete response, the disease control rate was 76.8% (partial response rate 21.4%, the stable disease
rate 55.4%). Histopathology and the number of relapsed site did not affect the response rate. Median PFS
was 5.3 months. The number of cycles of leukopenia and neutropenia accounted for 32.5% and 34.1%,
respectively, of which only 1.4% was in grade 3 and grade 4. Other common nonhematologic side effects
were nausea/vomiting (15.2%); diarrhea (4.7%) and gastritis (2.8%), which were mild and did not affect the
treatment course.
Conclusion: Vinorelbine monotherapy is an effective option in relapsed NSCLC patients with a good
safety profile.
Keywords: Lung cancer, vinorelbine monotherapy, NSCLC, recurrence
Tài liệu tham khảo
GLOBOCAN 2020. Available from: https://gco. iarc.fr/today/data/factsheets/populations/900- world-fact-sheets.pdf.
GLOBOCAN 2020. Available from: https://gco. iarc.fr/today/data/factsheets/populations/704- viet-nam-fact-sheets.pdf.
Mai NT. Chemotherapy in advanced or recurrent non small cell lung cancer. Lung cancer 2008
Dehkordi A, Heydarnejad MS, Fatehi DJOmj. Quality of life in cancer patients undergoing chemotherapy. 2009;24:204
Wozniak AJ. Single-agent vinorelbine in the treatment of non-small cell lung cancer. in Seminars in oncology. 1999.
Jones SF, Burris III HAJAoP. Vinorelbine: a new antineoplastic drug for the treatment of nonsmall-cell lung cancer. 1996;30:501-506
Vokes EE, Rosenberg RK, Jahanzeb M, Craig JB, Gralla RJ, Belani CP, et al. Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer. 1995;13:637-644
Crawford J. Update: vinorelbine (navelbine) in non-small cell lung cancer. in Seminars in oncology. 1996.
Gridelli CJTo. The ELVIS Trial: A phase III study of single‐agent vinorelbine as first‐line treatment in elderly patients with advanced non‐ small cell lung cancer. 2001;6:4-7
Describing the clinicopathological characteristics of primary lung cancer. Vietnam Oncology Journal 2011:195-199
Nhan NT, Evaluating the treatment results of Gemcitabin-Carboplatin regimen in stage IIIB, IV non-small cell lung cancer, in Hanoi Medical University. 2012.
Kiem NK, Thang PL, Binh PV. Video assisted thoracic surgery lobectomy in primary lung cancer at National Cancer Hospital. Vietnam Oncology Journal 2014;2:272-277
Saisho S, Yasuda K, Maeda A, Yukawa T, Okita R, Hirami Y, et al. Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/ adjuvant chemotherapy. 2013;16:166-172
Tung HT, Evaluating the treatment results in stage IIB-IIIA non-small cell lung cancer at National Cancer Hospital between 2002 and 2006. 2006, Hanoi Medical University.
Huy BQ, Evaluating the treatment results of Gemcitabine-Cisplatin regimen in stage IIIB, IV non-small cell lung cancer at National Cancer Hospital. Hanoi Medical University.
| Đã xuất bản | 12-01-2025 | |
| Toàn văn |
|
|
| Ngôn ngữ |
|
|
| Số tạp chí | Số 69 (2021) | |
| Phân mục | Nghiên cứu | |
| DOI | 10.38103/jcmhch.2021.69.4 | |
| Từ khóa | Keywords: Lung cancer, vinorelbine monotherapy, NSCLC, recurrence |
công trình này được cấp phép theo Creative Commons Attribution-phi thương mại-NoDerivatives 4.0 License International .
Bản quyền (c) 2021 Tạp chí Y học lâm sàng Bệnh viện Trung Ương Huế